Health indices were flat and balanced on another heavy earnings day Thursday.
First a non-earnings item, Progenics Pharmaceuticals (PGNX Quote) surged $2.61, or 32.5%, to $10.64 Thursday. The stock was already up nearly 19% from Monday's open prior to Thursday's rally, as investors showed enthusiasm for the prospects of Wyeth (WYE Quote) and Progenics' Relistor for treatment of constipation induced by pain-killers in patients who are receiving palliative care.
The Food and Drug Administration is expected to make a decision on the drug -- previously delayed from January of this year -- on or by April 30. On Thursday, the European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) recommended the agency approve Relistor. ...
Recent Comments
| Dow Jones | S&P 500 | NASDAQ | 10-Year Note | |
|---|---|---|---|---|
| 10,311.06 | 1,100.64 | 2,205.26 | 35.46 |
Oil *
73.69
|
|
UP
2.80
|
UP
4.57
|
UP
25.21
|
UP
0.59
|
10 Yr
3.55%
SPDR Gold
108.80
|
|
+0.03%
|
+0.42%
|
+1.16%
|
+1.69%
|
Data delayed 20 minutes |
Connect with TheStreet